APO Research
Talk to an analyst

APO RESEARCH · REPORT

α4β7 Integrin Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global α4β7 Integrin Antagonists Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry Researchα4β7 Integrin Antagonists Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal α4β7 Integrin Antagonists Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal α4β7 Integrin Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal α4β7 Integrin Antagonists Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal α4β7 Integrin Antagonists Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global α4β7 Integrin Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for α4β7 Integrin Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for α4β7 Integrin Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for α4β7 Integrin Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the α4β7 Integrin Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the α4β7 Integrin Antagonists market include Biogen, Novartis, Sandoz and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global α4β7 Integrin Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of α4β7 Integrin Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents α4β7 Integrin Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the α4β7 Integrin Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

α4β7 Integrin Antagonists Segment by Company

Biogen

Novartis

Sandoz

Takeda

α4β7 Integrin Antagonists Segment by Type

Natalizumub

Vedolizumab

α4β7 Integrin Antagonists Segment by Application

Inflammatory Bowel Disease (IBD)

Multiple Sclerosis (MS)

Other

α4β7 Integrin Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global α4β7 Integrin Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions α4β7 Integrin Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify α4β7 Integrin Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze α4β7 Integrin Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global α4β7 Integrin Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of α4β7 Integrin Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of α4β7 Integrin Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the α4β7 Integrin Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global α4β7 Integrin Antagonists industry.

Chapter 3: Detailed analysis of α4β7 Integrin Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of α4β7 Integrin Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of α4β7 Integrin Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. α4β7 Integrin Antagonists Industry Trends Table 2. α4β7 Integrin Antagonists Industry Drivers Table 3. α4β7 Integrin Antagonists Industry Opportunities and Challenges Table 4. α4β7 Integrin Antagonists Industry Restraints Table 5. Global α4β7 Integrin Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global α4β7 Integrin Antagonists Revenue Share by Company (2021-2026) Table 7. Global α4β7 Integrin Antagonists Sales Volume by Company (K Units) & (2021-2026) Table 8. Global α4β7 Integrin Antagonists Sales Volume Share by Company (2021-2026) Table 9. Global α4β7 Integrin Antagonists Average Price (US$/Unit) of Company (2021-2026) Table 10. Global α4β7 Integrin Antagonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global α4β7 Integrin Antagonists Key Company Manufacturing Base & Headquarters Table 12. Global α4β7 Integrin Antagonists Company, Product Type & Application Table 13. Global α4β7 Integrin Antagonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global α4β7 Integrin Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Natalizumub Table 18. Significant Companies of Vedolizumab Table 19. Global α4β7 Integrin Antagonists Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global α4β7 Integrin Antagonists Sales Volume by Type (2021-2026) & (K Units) Table 21. Global α4β7 Integrin Antagonists Sales Volume by Type (2027-2032) & (K Units) Table 22. Global α4β7 Integrin Antagonists Sales Volume Share by Type (2021-2026) Table 23. Global α4β7 Integrin Antagonists Sales Volume Share by Type (2027-2032) Table 24. Global α4β7 Integrin Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global α4β7 Integrin Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global α4β7 Integrin Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global α4β7 Integrin Antagonists Sales Value Share by Type (2021-2026) Table 28. Global α4β7 Integrin Antagonists Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Inflammatory Bowel Disease (IBD) Table 30. Significant Companies of Multiple Sclerosis (MS) Table 31. Significant Companies of Other Table 32. Global α4β7 Integrin Antagonists Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global α4β7 Integrin Antagonists Sales Volume by Application (2021-2026) & (K Units) Table 34. Global α4β7 Integrin Antagonists Sales Volume by Application (2027-2032) & (K Units) Table 35. Global α4β7 Integrin Antagonists Sales Volume Share by Application (2021-2026) Table 36. Global α4β7 Integrin Antagonists Sales Volume Share by Application (2027-2032) Table 37. Global α4β7 Integrin Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global α4β7 Integrin Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global α4β7 Integrin Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global α4β7 Integrin Antagonists Sales Value Share by Application (2021-2026) Table 41. Global α4β7 Integrin Antagonists Sales Value Share by Application (2027-2032) Table 42. Global α4β7 Integrin Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global α4β7 Integrin Antagonists Sales by Region (2021-2026) & (K Units) Table 44. Global α4β7 Integrin Antagonists Sales Market Share by Region (2021-2026) Table 45. Global α4β7 Integrin Antagonists Sales by Region (2027-2032) & (K Units) Table 46. Global α4β7 Integrin Antagonists Sales Market Share by Region (2027-2032) Table 47. Global α4β7 Integrin Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global α4β7 Integrin Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global α4β7 Integrin Antagonists Sales Value Share by Region (2021-2026) Table 50. Global α4β7 Integrin Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global α4β7 Integrin Antagonists Sales Value Share by Region (2027-2032) Table 52. Global α4β7 Integrin Antagonists Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global α4β7 Integrin Antagonists Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global α4β7 Integrin Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global α4β7 Integrin Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global α4β7 Integrin Antagonists Sales by Country (2021-2026) & (K Units) Table 57. Global α4β7 Integrin Antagonists Sales Market Share by Country (2021-2026) Table 58. Global α4β7 Integrin Antagonists Sales by Country (2027-2032) & (K Units) Table 59. Global α4β7 Integrin Antagonists Sales Market Share by Country (2027-2032) Table 60. Global α4β7 Integrin Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global α4β7 Integrin Antagonists Sales Value Market Share by Country (2021-2026) Table 62. Global α4β7 Integrin Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global α4β7 Integrin Antagonists Sales Value Market Share by Country (2027-2032) Table 64. Biogen Company Information Table 65. Biogen Business Overview Table 66. Biogen α4β7 Integrin Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Biogen α4β7 Integrin Antagonists Product Portfolio Table 68. Biogen Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis α4β7 Integrin Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis α4β7 Integrin Antagonists Product Portfolio Table 73. Novartis Recent Development Table 74. Sandoz Company Information Table 75. Sandoz Business Overview Table 76. Sandoz α4β7 Integrin Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sandoz α4β7 Integrin Antagonists Product Portfolio Table 78. Sandoz Recent Development Table 79. Takeda Company Information Table 80. Takeda Business Overview Table 81. Takeda α4β7 Integrin Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Takeda α4β7 Integrin Antagonists Product Portfolio Table 83. Takeda Recent Development Table 84. Key Raw Materials Table 85. Raw Materials Key Suppliers Table 86. α4β7 Integrin Antagonists Distributors List Table 87. α4β7 Integrin Antagonists Customers List Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. α4β7 Integrin Antagonists Product Image Figure 2. Global α4β7 Integrin Antagonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global α4β7 Integrin Antagonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global α4β7 Integrin Antagonists Sales (2021-2032) & (K Units) Figure 5. Global α4β7 Integrin Antagonists Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global α4β7 Integrin Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Natalizumub Image Figure 10. Vedolizumab Image Figure 11. Global α4β7 Integrin Antagonists Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global α4β7 Integrin Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global α4β7 Integrin Antagonists Sales Volume Share by Type (2021-2032) Figure 14. Global α4β7 Integrin Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global α4β7 Integrin Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global α4β7 Integrin Antagonists Sales Value Share by Type (2021-2032) Figure 17. Inflammatory Bowel Disease (IBD) Image Figure 18. Multiple Sclerosis (MS) Image Figure 19. Other Image Figure 20. Global α4β7 Integrin Antagonists Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global α4β7 Integrin Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global α4β7 Integrin Antagonists Sales Volume Share by Application (2021-2032) Figure 23. Global α4β7 Integrin Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global α4β7 Integrin Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global α4β7 Integrin Antagonists Sales Value Share by Application (2021-2032) Figure 26. Global α4β7 Integrin Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global α4β7 Integrin Antagonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global α4β7 Integrin Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global α4β7 Integrin Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America α4β7 Integrin Antagonists Sales Value (2021-2032) & (US$ Million) Figure 31. North America α4β7 Integrin Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe α4β7 Integrin Antagonists Sales Value (2021-2032) & (US$ Million) Figure 33. Europe α4β7 Integrin Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific α4β7 Integrin Antagonists Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific α4β7 Integrin Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America α4β7 Integrin Antagonists Sales Value (2021-2032) & (US$ Million) Figure 37. South America α4β7 Integrin Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa α4β7 Integrin Antagonists Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa α4β7 Integrin Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. α4β7 Integrin Antagonists Value Chain Figure 125. Manufacturing Cost Structure Figure 126. α4β7 Integrin Antagonists Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Natalizumub
  • Vedolizumab
Applications
  • Inflammatory Bowel Disease (IBD)
  • Multiple Sclerosis (MS)
  • Other
Companies covered
  • Biogen
  • Novartis
  • Sandoz
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global α4β7 Integrin Antagonists Sales Value (2021-2032)
  4. 1.2.2 Global α4β7 Integrin Antagonists Sales Volume (2021-2032)
  5. 1.2.3 Global α4β7 Integrin Antagonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 α4β7 Integrin Antagonists Market Dynamics
  1. 2.1 α4β7 Integrin Antagonists Industry Trends
  2. 2.2 α4β7 Integrin Antagonists Industry Drivers
  3. 2.3 α4β7 Integrin Antagonists Industry Opportunities and Challenges
  4. 2.4 α4β7 Integrin Antagonists Industry Restraints
3 α4β7 Integrin Antagonists Market by Company
  1. 3.1 Global α4β7 Integrin Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global α4β7 Integrin Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global α4β7 Integrin Antagonists Sales Volume by Company (2021-2026)
  4. 3.4 Global α4β7 Integrin Antagonists Average Price by Company (2021-2026)
  5. 3.5 Global α4β7 Integrin Antagonists Company Ranking (2024-2026)
  6. 3.6 Global α4β7 Integrin Antagonists Company Manufacturing Base and Headquarters
  7. 3.7 Global α4β7 Integrin Antagonists Company Product Type and Application
  8. 3.8 Global α4β7 Integrin Antagonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global α4β7 Integrin Antagonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 α4β7 Integrin Antagonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 α4β7 Integrin Antagonists Market by Type
  1. 4.1 α4β7 Integrin Antagonists Type Introduction
  2. 4.1.1 Natalizumub
  3. 4.1.2 Vedolizumab
  4. 4.2 Global α4β7 Integrin Antagonists Sales Volume by Type
  5. 4.2.1 Global α4β7 Integrin Antagonists Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global α4β7 Integrin Antagonists Sales Volume by Type (2021-2032)
  7. 4.2.3 Global α4β7 Integrin Antagonists Sales Volume Share by Type (2021-2032)
  8. 4.3 Global α4β7 Integrin Antagonists Sales Value by Type
  9. 4.3.1 Global α4β7 Integrin Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global α4β7 Integrin Antagonists Sales Value by Type (2021-2032)
  11. 4.3.3 Global α4β7 Integrin Antagonists Sales Value Share by Type (2021-2032)
5 α4β7 Integrin Antagonists Market by Application
  1. 5.1 α4β7 Integrin Antagonists Application Introduction
  2. 5.1.1 Inflammatory Bowel Disease (IBD)
  3. 5.1.2 Multiple Sclerosis (MS)
  4. 5.1.3 Other
  5. 5.2 Global α4β7 Integrin Antagonists Sales Volume by Application
  6. 5.2.1 Global α4β7 Integrin Antagonists Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global α4β7 Integrin Antagonists Sales Volume by Application (2021-2032)
  8. 5.2.3 Global α4β7 Integrin Antagonists Sales Volume Share by Application (2021-2032)
  9. 5.3 Global α4β7 Integrin Antagonists Sales Value by Application
  10. 5.3.1 Global α4β7 Integrin Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global α4β7 Integrin Antagonists Sales Value by Application (2021-2032)
  12. 5.3.3 Global α4β7 Integrin Antagonists Sales Value Share by Application (2021-2032)
6 α4β7 Integrin Antagonists Regional Sales and Value Analysis
  1. 6.1 Global α4β7 Integrin Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global α4β7 Integrin Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global α4β7 Integrin Antagonists Sales by Region: 2021-2026
  4. 6.2.2 Global α4β7 Integrin Antagonists Sales by Region (2027-2032)
  5. 6.3 Global α4β7 Integrin Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global α4β7 Integrin Antagonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global α4β7 Integrin Antagonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global α4β7 Integrin Antagonists Sales Value by Region (2027-2032)
  9. 6.5 Global α4β7 Integrin Antagonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America α4β7 Integrin Antagonists Sales Value (2021-2032)
  12. 6.6.2 North America α4β7 Integrin Antagonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe α4β7 Integrin Antagonists Sales Value (2021-2032)
  15. 6.7.2 Europe α4β7 Integrin Antagonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific α4β7 Integrin Antagonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific α4β7 Integrin Antagonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America α4β7 Integrin Antagonists Sales Value (2021-2032)
  21. 6.9.2 South America α4β7 Integrin Antagonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa α4β7 Integrin Antagonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa α4β7 Integrin Antagonists Sales Value Share by Country, 2025 VS 2032
7 α4β7 Integrin Antagonists Country-level Sales and Value Analysis
  1. 7.1 Global α4β7 Integrin Antagonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global α4β7 Integrin Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global α4β7 Integrin Antagonists Sales by Country (2021-2032)
  4. 7.3.1 Global α4β7 Integrin Antagonists Sales by Country (2021-2026)
  5. 7.3.2 Global α4β7 Integrin Antagonists Sales by Country (2027-2032)
  6. 7.4 Global α4β7 Integrin Antagonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global α4β7 Integrin Antagonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global α4β7 Integrin Antagonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt α4β7 Integrin Antagonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt α4β7 Integrin Antagonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt α4β7 Integrin Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen α4β7 Integrin Antagonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biogen α4β7 Integrin Antagonists Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis α4β7 Integrin Antagonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis α4β7 Integrin Antagonists Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Sandoz
  14. 8.3.1 Sandoz Company Information
  15. 8.3.2 Sandoz Business Overview
  16. 8.3.3 Sandoz α4β7 Integrin Antagonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sandoz α4β7 Integrin Antagonists Product Portfolio
  18. 8.3.5 Sandoz Recent Developments
  19. 8.4 Takeda
  20. 8.4.1 Takeda Company Information
  21. 8.4.2 Takeda Business Overview
  22. 8.4.3 Takeda α4β7 Integrin Antagonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Takeda α4β7 Integrin Antagonists Product Portfolio
  24. 8.4.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 α4β7 Integrin Antagonists Value Chain Analysis
  2. 9.1.1 α4β7 Integrin Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 α4β7 Integrin Antagonists Sales Mode & Process
  6. 9.2 α4β7 Integrin Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 α4β7 Integrin Antagonists Distributors
  9. 9.2.3 α4β7 Integrin Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst